LL-37 is the C-terminal 37-amino-acid fragment of human cathelicidin hCAP-18 — the body's only known cathelicidin antimicrobial peptide. Studied extensively for broad-spectrum antimicrobial, immunomodulatory and wound healing effects.

📊Clinical Studies & Results

LL-37 is the most extensively studied human cathelicidin peptide.

▪Grönberg et al. clinical study on hard-to-heal venous leg ulcers
▪Activity against MRSA and Gram-negative pathogens
▪Anti-viral activity against enveloped viruses including HIV-1 and influenza

LL-37 is a key research peptide for antimicrobial and wound healing studies.

🏆Benefits

Broad-spectrum antimicrobial activity
Neutralizes bacterial endotoxin (LPS)
Promotes wound re-epithelialization and angiogenesis
Modulates innate immune signaling

⚠️Possible Side Effects

▪Cytotoxicity to host cells at high concentrations
▪Transient injection-site reaction
▪Potential pro-inflammatory at high doses

🎯Ideal For

→Antimicrobial peptide development
→Chronic wound healing research
→Innate immunity studies
→Anti-biofilm research

LABORATORY REAGENT – FOR RESEARCH PURPOSES ONLY

This product is not a drug or food and should be handled by qualified professionals in laboratory conditions. All product information is provided for educational purposes only.

Description

Information:

The product (substance) isn't a food or diet supplement and is not suitable for human consumption.
Keep out of children's reach
Keep container tightly closed.
Store in a dry, cool and shaded place; protect from moisture.
Store only in the original container.
Avoid contact during pregnancy and breast feeding.
Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.